Clinical trial of nafoxidine in advanced breast cancer

Med Pediatr Oncol. 1978;4(2):123-6. doi: 10.1002/mpo.2950040207.

Abstract

Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine. The drug was generally well tolerated with dermatitis being the major toxic effect. A partial response in 12 of 40 patients, or 30%, was achieved with a median duration of response of greater than five months.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / drug therapy*
  • Drug Hypersensitivity / etiology
  • Drug Therapy, Combination
  • Female
  • Humans
  • Middle Aged
  • Nafoxidine / adverse effects
  • Nafoxidine / therapeutic use*
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Prednisone / therapeutic use
  • Pyrrolidines / therapeutic use*
  • Receptors, Estrogen / drug effects

Substances

  • Pyrrolidines
  • Receptors, Estrogen
  • Nafoxidine
  • Prednisone